Abstract

Maintenance of genome integrity requires tight control of DNA damage response (DDR) signalling and repair, with phosphorylation and ubiquitination representing key elements. How these events are coordinated to achieve productive DNA repair remains elusive. Here we identify the ubiquitin-conjugating enzyme UBE2D3 as a regulator of ATM kinase-induced DDR that promotes non-homologous end-joining (NHEJ) at telomeres. UBE2D3 contributes to DDR-induced chromatin ubiquitination and recruitment of the NHEJ-promoting factor 53BP1, both mediated by RNF168 upon ATM activation. Additionally, UBE2D3 promotes NHEJ by limiting RNF168 accumulation and facilitating ATM-mediated phosphorylation of KAP1-S824. Mechanistically, defective KAP1-S824 phosphorylation and telomeric NHEJ upon UBE2D3-deficiency are linked to RNF168 hyperaccumulation and aberrant PP2A phosphatase activity. Together, our results identify UBE2D3 as a multi-level regulator of NHEJ that orchestrates ATM and RNF168 activities. Moreover, they reveal a negative regulatory circuit in the DDR that is constrained by UBE2D3 and consists of RNF168- and phosphatase-mediated restriction of KAP1 phosphorylation.

Ubiquitin system factors are critical regulators of DNA repair pathways. Through a functional genetic screen, the authors identify a novel role of ubiquitin-conjugating enzyme UBE2D3 in promoting DNA repair at deprotected telomeres by limiting the accumulation of RNF168 and promoting ample ATM-dependent phosphorylation of KAP1.

Details

Title
UBE2D3 facilitates NHEJ by orchestrating ATM signalling through multi-level control of RNF168
Author
Yalçin, Zeliha 1   VIAFID ORCID Logo  ; Lam, Shiu Yeung 1   VIAFID ORCID Logo  ; Peuscher, Marieke H. 1 ; van der Torre, Jaco 1   VIAFID ORCID Logo  ; Zhu, Sha 1 ; Iyengar, Prasanna V. 1 ; Salas-Lloret, Daniel 2   VIAFID ORCID Logo  ; de Krijger, Inge 1 ; Moatti, Nathalie 1 ; van der Lugt, Ruben 1 ; Falcone, Mattia 1   VIAFID ORCID Logo  ; Cerutti, Aurora 1 ; Bleijerveld, Onno B. 3   VIAFID ORCID Logo  ; Hoekman, Liesbeth 3   VIAFID ORCID Logo  ; González-Prieto, Román 4   VIAFID ORCID Logo  ; Jacobs, Jacqueline J. L. 1   VIAFID ORCID Logo 

 The Netherlands Cancer Institute, Division of Oncogenomics, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393) 
 Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000 0000 8945 2978) 
 The Netherlands Cancer Institute, Proteomics Facility, Amsterdam, the Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393) 
 Leiden University Medical Center, Department of Cell and Chemical Biology, Leiden, the Netherlands (GRID:grid.10419.3d) (ISNI:0000 0000 8945 2978); Universidad de Sevilla-CSIC-Universidad-Pablo de Olavide, Andalusian Center for Molecular Biology and regenerative Medicine (CABIMER), Sevilla, Spain (GRID:grid.427489.4) (ISNI:0000 0004 0631 1969); Universidad de Sevilla, Departamento de Biología Celular, Facultad de Biología, Sevilla, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229) 
Pages
5032
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3067102529
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.